# Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan

> **NCT00150332** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 24 (actual)

## Conditions studied

- Infections, Nosocomial

## Interventions

- **DRUG:** linezolid

## Key facts

- **NCT ID:** NCT00150332
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** —
- **Final completion:** 2006-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2011-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00150332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00150332, "Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00150332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*